Wedbush set a $223.00 price objective on Ascendis Pharma A/S (NASDAQ:ASND) in a research note released on Monday, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Ascendis Pharma A/S from a hold rating to a sell rating in a research report on Monday. Canaccord Genuity increased their price target on shares of Ascendis Pharma A/S from $133.00 to $144.00 and gave the stock a buy rating in a research report on Friday, May 31st. BidaskClub upgraded shares of Ascendis Pharma A/S from a buy rating to a strong-buy rating in a research report on Thursday, May 30th. Credit Suisse Group reduced their price target on shares of Ascendis Pharma A/S from $151.00 to $139.00 and set an outperform rating on the stock in a research report on Friday, March 29th. Finally, Evercore ISI began coverage on shares of Ascendis Pharma A/S in a research report on Monday, March 25th. They set an outperform rating on the stock. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $137.22.

NASDAQ ASND opened at $120.37 on Monday. The company has a current ratio of 22.32, a quick ratio of 22.32 and a debt-to-equity ratio of 0.02. The company has a market cap of $5.19 billion, a P/E ratio of -32.18 and a beta of 0.77. Ascendis Pharma A/S has a 1 year low of $53.21 and a 1 year high of $133.96.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.17) by $0.30. The business had revenue of $12.00 million for the quarter. Ascendis Pharma A/S had a negative net margin of 901.89% and a negative return on equity of 34.64%. Equities analysts expect that Ascendis Pharma A/S will post -5.07 EPS for the current year.

A number of institutional investors have recently modified their holdings of the business. FMR LLC boosted its position in Ascendis Pharma A/S by 11.6% in the first quarter. FMR LLC now owns 4,692,707 shares of the biotechnology company’s stock valued at $552,332,000 after buying an additional 489,461 shares in the last quarter. venBio Select Advisor LLC boosted its position in Ascendis Pharma A/S by 0.8% in the fourth quarter. venBio Select Advisor LLC now owns 1,980,000 shares of the biotechnology company’s stock valued at $124,047,000 after buying an additional 16,664 shares in the last quarter. Marshall Wace North America L.P. boosted its position in Ascendis Pharma A/S by 56.4% in the first quarter. Marshall Wace North America L.P. now owns 1,161,476 shares of the biotechnology company’s stock valued at $136,706,000 after buying an additional 418,717 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in Ascendis Pharma A/S by 208.2% in the first quarter. Artisan Partners Limited Partnership now owns 1,131,107 shares of the biotechnology company’s stock valued at $133,131,000 after buying an additional 764,160 shares in the last quarter. Finally, Westfield Capital Management Co. LP boosted its position in Ascendis Pharma A/S by 27.3% in the first quarter. Westfield Capital Management Co. LP now owns 686,545 shares of the biotechnology company’s stock valued at $80,806,000 after buying an additional 147,425 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Recommended Story: What are the reasons investors use put options?

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.